BioSpace News Archive

Nourianz (istradefylline) was given the thumbs-up as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “OFF” episodes.

It takes on average five years before the confirmatory trial is even started.

Partly because it’s an election year and partly because, well, drugs can be expensive, the topic of drug pricing is a hot-button issue.

IRLAB announced that the in-depth analysis of the data from the recently concluded Phase IIa study of IRL790 in Parkinson’s patients with L-dopa induced dyskinesia brings further evidence of the drug candidate’s ability to significantly and meaningfully improve daytime movement quality.

In late August it was announced that Klaas Bakker was appointed as the new Chief Medical Officer for Oncopeptides.

Several advances in the clinical portfolio

GB Sciences, Inc. announced the appointment to GB Sciences’ executive team of Darin Carpenter as the company’s new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.

OKYO Pharma Limited is pleased to announce potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of DED in mice.

The launch in Plano, Texas will provide a new resource for parents and kids seeking a more intensive, individualized, early approach to therapy

Alexion Pharmaceuticals announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET.